This abstract is part of the Presidential Symposium AN OPEN-LABEL, RANDOMISED, PHASE 3 STUDY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): POLLUX

被引：0

作者：

Dimopoulos, M. A. ^{[1
]}

Oriol, A. ^{[2
]}

Nahi, H. ^{[3
,4
]}

Miguel, J. S. ^{[5
]}

Bahlis, N. J. ^{[6
]}

Rabin, N. ^{[7
]}

Orlowski, R. ^{[8
]}

Komarnicki, M. ^{[9
]}

Suzuki, K. ^{[10
]}

Plesner, T. ^{[11
,12
]}

Samoilova, O. S. ^{[13
]}

Yoon, S. S. ^{[14
]}

Yehuda, D. B. ^{[15
]}

Richardson, P. G. ^{[16
]}

Goldschmidt, H. ^{[17
,18
]}

Reece, D. ^{[19
]}

Khokhar, N. ^{[20
]}

O'Rourke, L. ^{[20
]}

Chiu, C. ^{[20
]}

Qin, X. ^{[21
]}

Guckert, M. ^{[20
]}

Ahmadi, T. ^{[20
]}

Moreau, P. ^{[22
]}

机构：

[1] Univ Athens, Athens, Greece

[2] HGTiP, Inst Catala Oncol, Barcelona, Spain

[3] Karolinska Inst, Stockholm, Sweden

[4] Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[5] Univ Navarra Clin, CIMA, Pamplona, Spain

[6] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[7] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[9] Poznan Univ Med Sci, Dept Hematol & Stem Cell Transplantat, Poznan, Poland

[10] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[11] Vejle Hosp, Vejle, Denmark

[12] Univ Southern Denmark, Vejle, Denmark

[13] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[14] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[15] Hadassah Hebrew Univ Med Ctr, Hematol Dept, Jerusalem, Israel

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[17] Univ Hosp Heidelberg, Heidelberg, Germany

[18] German Canc Res Ctr, Heidelberg, Germany

[19] Princess Margaret Canc Ctr, CCRU, Toronto, ON, Canada

[20] Janssen Res & Dev, Spring House, PA USA

[21] Janssen Res & Dev, Horsham, PA USA

[22] Univ Hosp Hotel Dieu, Hematol, Nantes, France

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB2238

引用

页码：342 / 342

页数：1

共 50 条

[21] Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Stewart, A. K.
Rajkumar, S. V.
Dimopoulos, M. A.
Mihaylov, G. G.
Goranova-Marinova, V.
Rajnics, P.
Suvorov, A.
Jakubowiak, A. J.
San-Miguel, J. F.
Zojwalla, N.
Moreau, P.
Palumbo, A.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 20 - 20
[22] Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Plesner, Torben
Arkenau, Hendrik-Tobias
Gimsing, Peter
Krejcik, Jakub
Lemech, Charlotte
Minnema, Monique C.
Lassen, Ulrik
Laubach, Jacob P.
Palumbo, Antonio
Lisby, Steen
Basse, Linda
Wang, Jianping
Sasser, A. Kate
Guckert, Mary E.
de Boer, Carla
Khokhar, Nushmia Z.
Yeh, Howard
Clemens, Pamela L.
Ahmadi, Tahamtan
Lokhorst, Henk M.
Richardson, Paul G.
BLOOD, 2016, 128 (14) : 1821 - 1828
[23] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Richardson, Paul G.
Oriol, Albert
Beksac, Meral
Liberati, Anna Marina
Galli, Monica
Schjesvold, Fredrik
Lindsay, Jindriska
Weisel, Katja
White, Darrell
Facon, Thierry
Miguel, Jesus Son
Sunami, Kazutaka
O'Gorman, Peter
Sonneveld, Pieter
Robak, Pawel
Semochkin, Sergey
Schey, Steve
Yu, Xin
Doerr, Thomas
Bensmaine, Amine
Biyukov, Tsvetan
Peluso, Teresa
Zaki, Mohamed
Anderson, Kenneth
Dimopoulos, Meletios
LANCET ONCOLOGY, 2019, 20 (06): : 781 - 794
[24] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Dimopoulos, Meletios
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Yang, Hui
Klippel, Zandra
Zahlten-Kumeli, Anita
Usmani, Saad Z.
LANCET, 2020, 396 (10245): : 186 - 197
[25] Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Ailawadhi, Sikander
Paulus, Aneel
Alegria, Victoria R.
Laplant, Betsy
Moustafa, Muhamad Alhaj
Chapin, Dustin
Jackson, Keisha
Jani, Prachi
Ahmed, Salman
Edwards, Brett
Manna, Alak
Roy, Vivek
Sher, Taimur
Chanan-Khan, Asher A.
BLOOD, 2019, 134
[26] Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.
Kaufman, Jonathan L.
Dimopoulos, Meletios A.
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Moreau, Philippe
Sutherland, Heather J.
Iida, Shinsuke
Kim, Jin Seok
Prince, H. Miles
Rocafiguera, Albert Oriol
Bahlis, Nizar J.
Chari, Ajai
Avet-Loiseau, Herve
Chiu, Christopher
Soong, David
Ukropec, Jon
Qi, Ming
San Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study
Plesner, Torben
Arkenau, Hendrik-Tobias
Gay, Francesca Marianatal
Minnema, Monique C.
Boccadoro, Mario
Moreau, Philippe
Cavenagh, James D.
Perrot, Aurore
Laubach, Jacob
Ahmadi, Tahamtan
de Boer, Carla
Chen, Diana
Chiu, Christopher
Schecter, Jordan
Richardson, Paul G.
BLOOD, 2017, 130
[28] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Dimopoulos, Meletios A.
Moreau, Philippe
Palumbo, Antonio
Joshua, Douglas
Pour, Ludek
Hajek, Roman
Facon, Thierry
Ludwig, Heinz
Oriol, Albert
Goldschmidt, Hartmut
Rosinol, Laura
Straub, Jan
Suvorov, Aleksandr
Araujo, Carla
Rimashevskaya, Elena
Pika, Tomas
Gaidano, Gianluca
Weisel, Katja
Goranova-Marinova, Vesselina
Schwarer, Anthony
Minuk, Leonard
Masszi, Tamas
Karamanesht, Ievgenii
Offidani, Massimo
Hungria, Vania
Spencer, Andrew
Orlowski, Robert Z.
Gillenwater, Heidi H.
Mohamed, Nehal
Feng, Shibao
Chng, Wee-Joo
LANCET ONCOLOGY, 2016, 17 (01): : 27 - 38
[29] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Usmani, Saad Z.
Quach, Hang
Mateos, Maria-Victoria
Landgren, Ola
Leleu, Xavier
Siegel, David
Weisel, Katja
Gavriatopoulou, Maria
Oriol, Albert
Rabin, Neil
Nooka, Ajay
Qi, Ming
Beksac, Meral
Jakubowiak, Andrzej
Ding, Bifeng
Zahlten-Kumeli, Anita
Yusuf, Akeem
Dimopoulos, Meletios
LANCET ONCOLOGY, 2022, 23 (01): : 65 - 76
[30] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
Weisel, Katja C.
Miguel, Jesus San
Cook, Gordon
Leiba, Merav
Suzuki, Kenshi
Kumar, Shaji
Cavo, Michele
Avet-Loiseau, Herve
Quach, Hang
Hungria, Vania
Lentzsch, Suzanne
Hajek, Roman
Sonneveld, Pieter
Wu, Kaida
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →